DOJ Federal Drug Enforcement Policy and Scheduling

Federal drug enforcement in the United States operates through an interlocking framework of statute, administrative scheduling, and prosecutorial discretion that determines which substances are controlled, at what severity level, and how violations are charged. The Department of Justice and its component agency, the Drug Enforcement Administration, hold central authority over both the classification of controlled substances and the federal prosecution of drug offenses. This page covers the definition and scope of federal drug enforcement authority, the scheduling mechanism under the Controlled Substances Act, common enforcement scenarios, and the decision boundaries that shape charging and declination outcomes.

Definition and scope

Federal drug enforcement authority derives primarily from the Controlled Substances Act (CSA), codified at 21 U.S.C. §§ 801–904. Enacted in 1970 as Title II of the Comprehensive Drug Abuse Prevention and Control Act, the CSA established a unified federal framework that replaced a patchwork of prior statutes. The DOJ, acting through the DEA, administers the scheduling system and enforces federal drug law alongside U.S. Attorneys' Offices in each federal district.

The CSA divides controlled substances into five schedules — Schedule I through Schedule V — based on three statutory criteria:

1. Accepted medical use — whether the substance has a currently accepted medical application in treatment in the United States
2. Abuse potential — the relative likelihood of abuse compared to other substances
3. Safety and dependence liability — the risk of psychological or physiological dependence under conditions of abuse

Schedule I substances, such as heroin and lysergic acid diethylamide (LSD), carry findings of no accepted medical use and high abuse potential. Schedule V substances, such as certain cough preparations containing less than 200 milligrams of codeine per 100 milliliters (21 C.F.R. § 1308.15), occupy the lowest tier of restriction.

Marijuana (cannabis) remains a Schedule I substance under federal law as of the CSA's current codification, irrespective of state-level legalization statutes in jurisdictions such as California and Colorado. This federal-state conflict is a documented structural tension within enforcement practice.

How it works

The scheduling process involves both the DEA and the Food and Drug Administration (FDA). Under 21 U.S.C. § 811, the DEA may initiate a scheduling action — or respond to a petition from any party — by requesting a scientific and medical evaluation from the FDA's Department of Health and Human Services. The HHS evaluation is binding on the DEA with respect to scientific findings; the DEA retains scheduling discretion within those findings.

The operational enforcement structure functions as follows:

1. DEA field divisions conduct investigations, execute warrants, and make arrests under federal drug statutes
2. DEA headquarters coordinates scheduling actions, international operations, and diversion control
3. U.S. Attorneys' Offices receive referrals from the DEA and exercise prosecutorial discretion in deciding whether to charge, decline, or seek a plea
4. The DOJ Criminal Division's Narcotic and Dangerous Drug Section (NDDS) prosecutes major international drug trafficking organizations and coordinates multi-district cases
5. The DOJ Civil Division handles asset forfeiture litigation arising from drug enforcement actions

Federal mandatory minimum sentences apply to drug trafficking offenses. Under 21 U.S.C. § 841, trafficking 1 kilogram or more of heroin triggers a 10-year mandatory minimum for a first offense, rising to 20 years if death or serious injury results. These statutory thresholds directly constrain judicial sentencing discretion and are a primary factor in plea agreement negotiations.

Common scenarios

Federal drug enforcement actions fall into identifiable patterns based on the nature of the offense and the actors involved:

Large-scale trafficking organizations. The DEA and NDDS focus significant resources on dismantling transnational criminal organizations. Operations under 21 U.S.C. § 848 — the Continuing Criminal Enterprise (CCE) statute, also called the "drug kingpin" statute — target organizers of large-scale trafficking networks and carry a mandatory minimum of 20 years, with life imprisonment available for leading enterprises meeting the statute's threshold of 5 or more persons acting in concert.

Prescription drug diversion. The DEA's Diversion Control Division investigates unlawful distribution of Schedule II through V prescription substances, including opioids such as oxycodone and fentanyl. Practitioners and pharmacies operating under DEA registration are subject to administrative action, civil penalties, and criminal referral.

Conspiracy charges. Under 21 U.S.C. § 846, a defendant who agrees with one or more persons to commit a drug offense is subject to the same penalties as the underlying offense, without requiring proof of a completed act. This provision is among the most commonly charged federal drug statutes.

Money laundering nexus. Drug trafficking proceeds frequently generate parallel money laundering enforcement cases under 18 U.S.C. §§ 1956–1957, compounding exposure beyond the drug offense itself.

Decision boundaries

The DOJ's enforcement priorities shape which drug cases receive federal attention versus state or local handling. Several documented criteria govern federal versus state prosecution decisions:

• Quantity thresholds — Federal resources concentrate on cases meeting or exceeding statutory mandatory minimum trigger quantities
• Organizational scope — Cases involving interstate or international networks are more likely to receive federal handling than localized transactions
• Prior record — Defendants with prior federal drug convictions face enhanced penalties under 21 U.S.C. § 841(b), making recidivist cases attractive to federal prosecutors
• Cooperation value — The government's interest in a defendant's cooperation with ongoing investigations influences charging decisions and plea structures

The contrast between Schedule I and Schedule II treatment illustrates a critical enforcement boundary. Schedule II substances — including cocaine, methamphetamine, and fentanyl — have recognized (if restricted) medical uses, enabling DEA-licensed practitioners to prescribe them. Schedule I substances carry no such pathway, meaning any distribution or possession with intent to distribute constitutes a federal offense without the licensed-practitioner defense available for Schedule II violations.

Prosecutorial declination in drug cases occurs when federal interest is outweighed by the case's suitability for state prosecution, insufficient evidence to meet federal proof standards, or the defendant's cooperation value in a larger investigation. DOJ policy memoranda — including guidance documents issued by successive Attorneys General — have periodically shifted these thresholds, directing prosecutors toward or away from mandatory minimum charges depending on the administration's enforcement posture.